RESUMEN
The role of host-microbiota interactions in primary biliary cholangitis (PBC) has received increased attention. However, the impact of PBC on the oral microbiota and contribution of the oral microbiota to PBC are unclear. In this study, thirty-nine PBC patients without other diseases and 37 healthy controls (HCs) were enrolled and tested for liver functions and haematological variables. Saliva specimens were collected before and after brushing, microbiota was determined using 16S rDNA sequencing, metabolomics was profiled using Gas Chromatography-Mass Spectrometer (GC-MS), 80 cytokines were assayed using biochips, and inflammation inducibility was evaluated using OKF6 keratinocytes and THP-1 macrophages. Finally, the effect of ultrasonic scaling on PBC was estimated. Compared with HCs, PBC saliva had enriched taxa such as Bacteroidetes, Campylobacter, Prevotella and Veillonella and depleted taxa such as Enterococcaceae, Granulicatella, Rothia and Streptococcus. PBC saliva also had enriched sCD163, enriched metabolites such as 2-aminomalonic acid and 1-dodecanol, and depleted metabolites such as dodecanoic acid and propylene glycol. sCD163, 4-hydroxybenzeneacetic acid and 2-aminomalonic acid were significantly correlated with salivary cytokines, bacteria and metabolites. Salivary Veillonellaceae members, 2-aminomalonic acid, and sCD163 were positively correlated with liver function indicators such as serum alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT). PBC salivary microbes induced more soluble interleukin (IL)-6 receptor α (sIL-6Rα), sIL-6Rß and tumour necrosis factor ligand superfamily (TNFSF)13B from OKF6 keratinocytes, and PBC salivary supernatant induced more IL-6, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), chemokine (C-C motif) ligand (CCL)13, C-X-C motif chemokine (CXC)L1 and CXCL16 from THP-1 macrophages. Toothbrushing significantly reduced the expression of inflammatory cytokines such as IL-1ß, IL-8 and TNF-α and harmful metabolites such as cadaverine and putrescine in PBC but not HC saliva after P-value correction. The levels of ALP and bilirubin in PBC serum were decreased after ultrasonic scaling. Together, PBC patients show significant alterations in their salivary microbiota, likely representing one cause and treatment target of oral inflammation and worsening liver functions.
Asunto(s)
Disbiosis/etiología , Interacciones Microbiota-Huesped , Cirrosis Hepática Biliar/complicaciones , Microbiota , Saliva/microbiología , Biomarcadores , Estudios de Casos y Controles , Quimiocinas/metabolismo , Citocinas/metabolismo , Femenino , Interacciones Microbiota-Huesped/inmunología , Humanos , Mediadores de Inflamación/metabolismo , Queratinocitos/metabolismo , Cirrosis Hepática Biliar/diagnóstico , Cirrosis Hepática Biliar/etiología , Cirrosis Hepática Biliar/metabolismo , Pruebas de Función Hepática , Masculino , Metabolómica/métodos , Metagenoma , Metagenómica/métodos , Persona de Mediana EdadRESUMEN
Herbal medicines harbor essential therapeutic agents for the treatment of cholestasis. In this study, we have assessed the anticholestatic potential of Stachys pilifera Benth's (SPB's) hydroalcoholic extract encapsulated into liposomes using bile duct ligation- (BDL-) induced hepatic cholestasis in rats. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), malondialdehyde (MDA), total thiol (T-SH) content, protein carbonyl (PCO), total bilirubin (TBIL), albumin (ALB), and nitric oxide (NO) metabolite levels were measured in either liver tissue or plasma to assess liver damage. Moreover, expression of proinflammatory cytokines (IL-1ß and TNF-α) and liver fibrosis markers (TGF-ß and SM-α) which are driving forces of many liver disorders was also determined. The activity of AST, ALT, and ALP was significantly enhanced in the BDL group in comparison to the control group; however, treatment with liposomal (SPB) hydroalcoholic extract significantly reduced AST and ALT's activity. Increases in MDA, TBIL, and NO levels and T-SH content due to BDL were restored to control levels by liposomal (SPB) hydroalcoholic extract treatment. Similarly, hepatic and plasma oxidative marker MDA levels, significantly enhanced by BDL, were significantly decreased by liposomal (SPB) hydroalcoholic extract treatment. Moreover, histopathological findings further demonstrated a significant decrease in hepatic damage in the liposomal (SPB) hydroalcoholic extract-treated BDL group. In addition, liposomal (SPB) hydroalcoholic extract treatment decreased the liver expression of inflammatory cytokines (IL-1ß, TNF-α) and liver fibrosis markers (TGF-ß and SM-α). Since liposomal (SPB) hydroalcoholic extract treatment alleviated the BDL-induced injury of the liver and improved the hepatic structure and function more efficiently in comparison to free SPB hydroalcoholic extract, probable liposomal (SPB) hydroalcoholic extract exhibits required potential therapeutic value in protecting the liver against BDL-caused oxidative injury.
Asunto(s)
Antioxidantes/farmacología , Colestasis Intrahepática/tratamiento farmacológico , Hígado/efectos de los fármacos , Extractos Vegetales/farmacología , Stachys , Actinas/genética , Actinas/metabolismo , Animales , Antiinflamatorios/aislamiento & purificación , Antiinflamatorios/farmacología , Antifibróticos/aislamiento & purificación , Antifibróticos/farmacología , Antioxidantes/aislamiento & purificación , Colestasis Intrahepática/metabolismo , Colestasis Intrahepática/patología , Conducto Colédoco/cirugía , Citocinas/genética , Citocinas/metabolismo , Modelos Animales de Enfermedad , Mediadores de Inflamación/metabolismo , Ligadura , Liposomas , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática Biliar/tratamiento farmacológico , Cirrosis Hepática Biliar/metabolismo , Cirrosis Hepática Biliar/patología , Masculino , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/aislamiento & purificación , Carbonilación Proteica/efectos de los fármacos , Ratas Wistar , Stachys/química , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismoRESUMEN
It still remains unclear how antimitochondrial autoantibodies (AMA) are involved with immunopathogenesis of primary biliary cirrhosis (PBC). We have suggested the potential role of IgA-AMA in damage to epithelial cells in PBC. In the current study, we investigated whether IgA-AMA were detectable in sera and saliva of PBC patients, to examine the association between detectable IgA-type autoantibodies in sera or saliva and progression of liver diseases. Fifty-three patients with PBC were enrolled, and IgA-AMA in sera and saliva were sought by immunoblotting using pork heart mitochondria as antigens. The progression of PBC was determined as Scheuer's classification consisting of four histological stages. We found IgA-AMA, IgA-anti-PDC-E2, and IgA-anti-E3BP in 43/53 (81%), 37/53 (70%), and 35/53 (66%) sera of patients with PBC, but none of controls. The progression of PBC was statistically associated with presence of IgA-anti-PDC-E2 (P = 0.0124), but neither with IgA-AMA (P = 0.1296) nor anti-IgA-E3BP (P = 0.5973). In saliva, detectable IgA-AMA, IgA-anti-PDC-E2, and IgA-anti-E3BP were noted in 12/26 (46%), 6/26 (23%), and 11/26 (42%), respectively. Detection of IgA-anti-PDC-E2 was strongly associated with progression of PBC (P = 0.0002), whereas detection of IgA-AMA and IgA-anti-E3BP were not associated (P = 0.2145 and P = 0.5118). The current findings suggest that the presence of IgA-anti-PDC-E2 in sera or saliva might be associated with progression of PBC, although a prospective study with PBC patients with detectable IgA-anti-PDC-E2 at early stages will be required to conclude the contribution of IgA-anti-PDC-E2 to the progression of PBC.
Asunto(s)
Inmunoglobulina A Secretora/inmunología , Inmunoglobulina A/inmunología , Inmunoglobulina A/metabolismo , Cirrosis Hepática Biliar/inmunología , Cirrosis Hepática Biliar/patología , Mitocondrias/inmunología , Saliva/inmunología , Progresión de la Enfermedad , Femenino , Humanos , Cirrosis Hepática Biliar/metabolismo , Masculino , Persona de Mediana Edad , Síndrome de Sjögren/diagnóstico , Síndrome de Sjögren/inmunologíaRESUMEN
Serum anti-mitochondrial antibody type 2 (AMA-M2) is considered as a pivotal biomarker for the diagnosis of primary biliary cholangitis (PBC). However, serological tests have many limitations, including inconvenience, invasiveness, and infection risks. Thus, a less invasive approach to detect AMA-M2 titer is desirable. We examined salivary AMA-M2 of potential PBC patients and found that AMA-M2 could be detected only in saliva of serum AMA-M2-positive PBC patients, but not in saliva of serum AMA-M2-negative PBC patients, oral lichen planus patients (OLP) patients, or healthy controls. Furthermore, the concentration of salivary AMA-M2 was positively correlated with the amount of serum AMA-M2 in patients. The salivary inflammatory cytokines were increased in the PBC, consistent with the results of serum test. These findings indicated that saliva might be a less invasive and cost-effective medium to accurately test for AMA-M2 levels and this is a promising development for the diagnosis and monitoring of PBC.
Asunto(s)
Autoanticuerpos/inmunología , Biomarcadores , Cirrosis Hepática Biliar/diagnóstico , Cirrosis Hepática Biliar/inmunología , Mitocondrias/inmunología , Saliva/inmunología , Autoanticuerpos/metabolismo , Autoantígenos , Citocinas/metabolismo , Femenino , Humanos , Mediadores de Inflamación/metabolismo , Cirrosis Hepática Biliar/metabolismo , Pruebas de Función Hepática , Curva ROC , Saliva/metabolismoRESUMEN
Antipyrine metabolism depends on at least three isoenzymes of cytochrome P450 forming the main metabolites 3-OH-, 4-OH- and norantipyrine. We investigated to what extent antipyrine clearance and metabolite formation are impaired in two models of liver cirrhosis in the rat, namely micronodular cirrhosis induced by chronic exposure to phenobarbital/CCl4 and biliary cirrhosis induced by bile duct ligation. Salivary antipyrine clearance was decreased to a similar extent in cirrhosis induced by CCl4 and bile duct ligation (-35%). Clearance for production of 3-OH-antipyrine was decreased in both models, while 4-hydroxylation was maintained. Metabolic clearance of both 3-OH-antipyrine and 4-OH-antipyrine in vivo correlated with their clearance in vitro (r = 0.658 and r = 0.583) but not with that of norantipyrine. The microsomal cholesterol content was increased by 16% and 90% in CCl4 and bile duct-ligated cirrhotic rats (P < 0.001), respectively. Membrane fluidity, expressed as the ratio of phospholipids to cholesterol, correlated with the in vivo clearance for production of norantipyrine (r = 0.841) but not of 3-OH- or 4-OH-antipyrine, while clearance in vitro was not related to altered lipid composition. Our results demonstrate that the cytochrome P450 isoenzymes responsible for the different pathways of antipyrine metabolism are affected to different extents by cirrhosis. Alterations in intrinsic clearance explain only part of the loss of hepatocellular function. Altered lipid composition contributes to this loss of function but other factors, among them loss of hepatocytes and changes in microcirculation, could be more important determinants of the decrease in xenobiotic metabolism in cirrhosis.
Asunto(s)
Antipirina/metabolismo , Cirrosis Hepática Biliar/metabolismo , Cirrosis Hepática Experimental/metabolismo , Animales , Antipirina/farmacocinética , Antipirina/orina , Ácidos y Sales Biliares/sangre , Pruebas Respiratorias , Tetracloruro de Carbono , Lípidos/análisis , Cirrosis Hepática Biliar/patología , Cirrosis Hepática Experimental/patología , Masculino , Fluidez de la Membrana , Microsomas Hepáticos/metabolismo , Microsomas Hepáticos/ultraestructura , Modelos Biológicos , Tamaño de los Órganos , Fenobarbital , Ratas , Ratas Sprague-Dawley , Saliva/metabolismoRESUMEN
Hydroxyzine, a potent H1-receptor antagonist often used for relief of pruritus in patients with hepatic dysfunction, was studied in eight patients, mean age 53.4 +/- SD 11.2 years, with primary biliary cirrhosis. The patients ingested a single dose of hydroxyzine, 0.7 mg/kg (mean dose 43.9 +/- 6.6 mg). Before the dose, then hourly for 6 hours, every 2 hours from 6-12 hours, at 24 hours, and every 24 hours for 6 days, serum hydroxyzine and cetirizine were measured and an intradermal injection of 0.01 mL of a 0.1 mg/mL solution of histamine phosphate was performed. Wheals and flares were traced at 10 minutes and the areas were calculated. Mean peak hydroxyzine levels of 116.5 +/- 60.6 ng/mL occurred at 2.3 +/- 0.7 hours and mean peak cetirizine levels of 500.4 +/- 302.0 ng/mL occurred at 4.8 +/- 2.8 hours. The mean serum elimination half-life of hydroxyzine was 36.6 +/- 13.1 hours, and the mean serum elimination half-life of cetirizine was 25.0 +/- 8.2 hours. The mean hydroxyzine clearance rate was 8.65 +/- 7.46 mL/min/kg, and the mean volume of distribution was 22.7 +/- 13.3 L/kg. The mean wheal area was suppressed (P less than 0.01) from 1 to 120 hours, with maximal suppression from 2 to 48 hours. The mean flare area was suppressed from 1 to 144 hours, with maximal suppression from 3 to 24 hours (P less than 0.01). All patients became sleepy from 0.5 to 6 hours. Blurred vision, dizziness and dry mouth each occurred in two patients. Hydroxyzine elimination is impaired in patients with primary biliary cirrhosis.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Hidroxizina/farmacocinética , Cirrosis Hepática Biliar/metabolismo , Adulto , Anciano , Cetirizina , Cromatografía Líquida de Alta Presión , Femenino , Semivida , Histamina , Antagonistas de los Receptores Histamínicos H1/farmacocinética , Humanos , Hidroxizina/análogos & derivados , Hidroxizina/farmacología , Masculino , Persona de Mediana Edad , Pruebas CutáneasRESUMEN
The intestinal absorption and hepatic metabolism of vitamin D were studied in a woman with icteric primary biliary cirrhosis (PBC) complicated by pronounced bone pain and muscle weakness due to vitamin-D deficiency. The patient had a markedly reduced intestinal absorption of vitamin D, while the 25-hydroxylation of this vitamin was found to be normal despite the presence of longstanding icterus. The malabsorption of fat-soluble compounds secondary to the cholestasis was probably further impaired by several years of cholestyramine treatment. Administration of 1.25-(OH)2D3 increased intestinal calcium absorption, normalized serum calcium and increased bone mineral content of the proximal tibia. Furthermore, drastic improvement of muscle weakness and relief of bone pain were observed. It is recommended that repeated measurements of serum 25-(OH)D should be carried out in patients with PBC, and especially in those treated with cholestyramine. In certain vitamin D deficient patients, studies using radio-labelled vitamin D may provide clinically valuable information as to the exact site of the underlying disturbances.
Asunto(s)
Cirrosis Hepática Biliar/complicaciones , Hígado/metabolismo , Deficiencia de Vitamina D/etiología , Resina de Colestiramina/efectos adversos , Femenino , Humanos , Absorción Intestinal/efectos de los fármacos , Cirrosis Hepática Biliar/tratamiento farmacológico , Cirrosis Hepática Biliar/metabolismo , Persona de Mediana Edad , Osteomalacia/etiología , Vitamina D/metabolismo , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/tratamiento farmacológico , Deficiencia de Vitamina D/metabolismoRESUMEN
Oral vitamin D3 was poorly absorbed by 4 out of 6 patients with primary biliary cirrhosis; absorption was negatively correlated with faecal fat excretion. 25-hydroxylation of vitamin D3 given by mouth or intravenously was not impaired in the patients compared with controls of similar vitamin-D nutritional status. Urinary radioactivity derived from the intravenous dose of vitamin D3 was significantly greater in patients than in controls and was positively correlated with the serum-bilirubin concentration. Excretion in the urine may lead to loss of administered and endogenous vitamin D and thus contribute to vitamin-D deficiency in patients with primary biliary cirrhosis.
Asunto(s)
Colecalciferol/metabolismo , Cirrosis Hepática Biliar/metabolismo , Administración Oral , Adulto , Anciano , Radioisótopos de Carbono , Colecalciferol/administración & dosificación , Colecalciferol/orina , Heces/análisis , Humanos , Hidroxilación , Inyecciones Intravenosas , Absorción Intestinal , Marcaje Isotópico , Metabolismo de los Lípidos , Lípidos/análisis , Persona de Mediana EdadRESUMEN
The disposition of antipyrine is altered and may be a prognostic factor in the presence of various types of hepatic dysfunction. The object of the present study was to investigate whether antipyrine clearance and metabolite formation are useful to detect altered metabolic function in primary biliary cirrhosis. Saliva clearance of antipyrine and the formation clearance of antipyrine metabolites (hydroxymethylantipyrine, HMA; norantipyrine, NORA; and 4-hydroxyantipyrine, OHA) were investigated in a group of 34 women with biopsy-proven PBC (mean age 60 years; range 39-87 years) and in 15 healthy control women (mean age 62 years; range 46-78 years). Parameters of antipyrine clearance of patients in stage I and II were similar to those observed in healthy subjects. When compared to patients in stage I, patients in advanced stages showed a reduction in antipyrine clearance (-29% and -44% in stages III and IV, respectively) and increases in antipyrine half-life (+24% and +75% in stages III and IV, respectively). The reduction in antipyrine clearance was due to a reduction in the formation of all three antipyrine metabolites, with the formation clearance of both HMA and NORA decreasing to a slightly greater extent than that of OHA. Antipyrine clearance correlated significantly with serum bilirubin (P < 0.017) and the Mayo risk score (P < 0.001). Logistic regression analysis indicated that antipyrine clearance was an independent predictor of the histological stage of the disease (P < 0.001). Antipyrine clearance and metabolite formation is a sensitive parameter for assessing hepatic metabolic function in primary biliary cirrhosis.
Asunto(s)
Antipirina/metabolismo , Cirrosis Hepática Biliar/diagnóstico , Cirrosis Hepática Biliar/metabolismo , Saliva/química , Adulto , Anciano , Anciano de 80 o más Años , Antipirina/análisis , Bilirrubina/sangre , Biopsia , Estudios de Casos y Controles , Femenino , Humanos , Cirrosis Hepática Biliar/clasificación , Modelos Logísticos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Factores de Riesgo , Índice de Severidad de la EnfermedadRESUMEN
Primary biliary cirrhosis, or chronic destructive nonsuppurative cholangitis, is a condition of chronic cholestasis, in which small intrahepatic bile ducts in the portal zones of the liver become progressively destroyed. The etiology of primary biliary cirrhosis is unknown, but the observation of (a) mitochondrial antibody, (b) elevated serum levels of IgM and (c) circulating immune complexes and (d) impaired lymphocyte transformation (- cooperation) strongly suggest, that disordered immune responses play a major role in the initiation or progression of this chronic hepatic lesion.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Cirrosis Hepática Biliar/inmunología , Fosfatasa Alcalina/metabolismo , Anticuerpos/inmunología , Formación de Anticuerpos , Complejo Antígeno-Anticuerpo/inmunología , Antígenos Bacterianos/inmunología , Canalículos Biliares/ultraestructura , Colestasis/etiología , Reacciones Cruzadas , Granuloma de Células Gigantes/etiología , Humanos , Inmunoglobulina M/análisis , Cirrosis Hepática Biliar/metabolismo , Mitocondrias/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Linfocitos T Reguladores/inmunología , gamma-Glutamiltransferasa/metabolismoRESUMEN
Bone histology and intestinal absorption of 25-hydroxyvitamin D3 (25-OHD) were investigated in 11 patients with primary biliary cirrhosis (P.B.C.). 4 patients had osteomalacia, and all these had received long-term cholestyramine. Plasma-25-hydroxyvitamin-D (25-OHD) concentrations after an oral dose of 25-OHD3 were significantly lower in the patients with P.B.C. (especially those with osteomalacia) than in normal controls. Serum calcium and urinary calcium excretion were lower, and serum-alkaline-phosphatase higher, in patients with osteomalacia. It is suggested that absorption of 25-OHD undergoing enterohepatic circulation and of dietary vitamin D is reduced in patients with P.B.C. Absorption of 25-OHD is further decreased by cholestyramine and the development of osteomalacia is thus hastened.
Asunto(s)
Hidroxicolecalciferoles/metabolismo , Absorción Intestinal , Cirrosis Hepática Biliar/metabolismo , Osteomalacia/etiología , Anciano , Fosfatasa Alcalina/sangre , Bilirrubina/sangre , Huesos/patología , Calcio/metabolismo , Resina de Colestiramina/efectos adversos , Resina de Colestiramina/uso terapéutico , Femenino , Humanos , Hidroxicolecalciferoles/sangre , Cirrosis Hepática Biliar/tratamiento farmacológico , Cirrosis Hepática Biliar/patología , Síndromes de Malabsorción/inducido químicamente , Síndromes de Malabsorción/complicaciones , Masculino , Persona de Mediana Edad , Osteomalacia/metabolismo , Osteomalacia/patología , Deficiencia de Vitamina D/complicaciones , Deficiencia de Vitamina D/etiologíaRESUMEN
Sjögren's syndrome is an autoimmune condition affecting the lacrimal and salivary glands and can be associated with rheumatoid arthritis and primary biliary cirrhosis. Parotid salivas collected from patients and normal controls were analysed for lactoferrin, IgA and beta2-microglobulin (measured by ELISA), and cystatin (measured by a enzyme inhibition assay). Output data provided less variable means, whilst expressing results as a proportion of the total protein provided greater specificity as markers for Sjögren's syndrome. Levels of specificity for IgA, lactoferrin and beta2-microglobulin were all high (100, 95 and 100%, respectively). Sensitivity levels of these markers (but not cystatin) tended to be similar for Sjögren's syndrome secondary to primary biliary cirrhosis (IgA, 25%; lactoferrin, 63%; and beta2-microglobulin, 50%), compared to Sjögren's syndrome secondary to connective tissue diseases such as rheumatoid arthritis (IgA, 50%; lactoferrin, 86%; and beta2-microglobulin; 38%).